Welcome to our dedicated page for Innospec SEC filings (Ticker: IOSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Innospec Inc. (NASDAQ: IOSP), an international specialty chemicals company. These documents offer detailed information about the company’s operations across its Performance Chemicals, Fuel Specialties and Oilfield Services segments, as well as its capital structure and governance.
Innospec’s SEC filings include periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited or reviewed financial statements, segmental data and discussions of results. Investors use these filings to examine net sales, gross profit and operating income by segment, along with notes on research and development, corporate costs and regional performance.
The company also files current reports on Form 8-K to disclose material events. Recent 8-K filings have covered the release of quarterly financial results and the declaration of semi-annual dividends on IOSP common stock. These filings identify the NASDAQ listing for Innospec’s common shares and provide details such as record and payment dates for dividends.
On Stock Titan, Innospec’s filings are updated as they are released on EDGAR, and AI-powered summaries can help explain the key points in lengthy documents. Users can quickly see which items relate to earnings, dividend actions, segment performance or other notable events. For those interested in topics such as non-GAAP measures, net cash, or segment trends in Performance Chemicals, Fuel Specialties and Oilfield Services, the filings page offers a structured way to review the company’s regulatory disclosures.
By combining real-time access to IOSP filings with AI-generated highlights, this page helps readers navigate Innospec’s official reporting without needing to read every line of each document.
Williams Patrick reported acquisition or exercise transactions in this Form 4 filing.
INNOSPEC INC. President & CEO Patrick Williams received an equity award of 20,846 Restricted Stock Units (RSUs) on February 23, 2026, recorded at a price of $0.00 per unit as a grant or award. These RSUs vest in full on February 23, 2029. Following this grant, his directly held common stock position is reported at 239,501 shares.
Jones David B. reported acquisition or exercise transactions in this Form 4 filing.
Innospec Inc. executive David B. Jones, who serves as SVP, General Counsel and Chief Compliance Officer, reported receiving an equity award tied to the company’s common stock. The filing shows a grant of 2,993 restricted stock units on February 23, 2026, which will vest in full on February 23, 2029.
After this grant, Jones is shown as beneficially owning 16,596 shares of Innospec common stock in total. This transaction reflects stock-based compensation rather than an open-market purchase or sale.
Blair Graeme reported acquisition or exercise transactions in this Form 4 filing.
Innospec Inc. reported that Head of Group Finance Graeme Blair received a grant of 520 units of phantom stock on February 23, 2026. Each phantom stock unit is economically equivalent to one share of Innospec common stock and is scheduled to settle in cash on the award’s expiration date based on the closing share price at that time.
MCROBBIE IAN MALCOLM reported acquisition or exercise transactions in this Form 4 filing.
Innospec Inc. executive Ian Malcolm McRobbie, Senior VP R&T, reported an award of 2,228 shares of phantom stock on February 23, 2026. This is a compensation grant recorded at a price of $0.00 per unit, bringing his reported phantom stock holdings to 2,228 units.
Each phantom stock share is economically equivalent to one share of Innospec common stock but will settle in cash rather than stock. The cash payout is scheduled for the award’s expiration date and will be based on the closing price of Innospec common stock on that date.
INNOSPEC INC. director Elizabeth K. Arnold reported an equity award from the company. She acquired 1,539 Restricted Stock Units (RSUs) at no purchase price as a grant in connection with her service as a non-employee director. These RSUs vest in full on February 23, 2029, meaning they convert into common shares for her at that time if conditions are met. Following this grant, her directly held common stock and RSU-related holdings total 6,376 shares, reflecting routine stock-based compensation rather than an open-market purchase or sale.
PARRETTE LESLIE J reported acquisition or exercise transactions in this Form 4 filing.
INNOSPEC INC. director Leslie J. Parrette reported an equity award of 1,539 shares of common stock in the form of Restricted Stock Units. The RSUs were granted in connection with Parrette’s service as a non-employee director and will vest in full on February 23, 2029. After this grant, Parrette directly holds 7,376 shares of common stock.
Innospec Inc. director David Landless received an equity award rather than buying shares on the market. He acquired 1,539 shares of common stock through a grant of restricted stock units that vest in full on February 23, 2029, for his service as a non-employee director. After this award, he holds 8,226 shares directly.
INNOSPEC INC. director Claudia Poccia reported an equity award on Form 4. She acquired 1,539 Restricted Stock Units (RSUs) tied to common stock, granted for her service as a non-employee director. These RSUs vest in full on February 23, 2029.
After this grant, Poccia directly holds a total of 6,627 shares or share-equivalent units of the company’s common stock. The transaction reflects a compensation-related stock award rather than an open-market purchase or sale.
Innospec director Milton C. Blackmore reported a mix of equity awards, option exercises, and share sales. He received 1,539 restricted stock units that vest in full on February 23, 2029 as compensation for his service as a non-employee director. On February 20, 2026, he exercised stock options for 1,030 shares of common stock at $44.18 per share and sold 1,030 shares of common stock in an open-market transaction at an average price of $81.8409 per share. After these transactions, his directly held common stock, including RSUs, was reported at 11,124 shares.
Innospec Inc. director Larry Padfield reported multiple equity transactions. He received a grant of 1,539 Restricted Stock Units that vest in full on February 23, 2029 for his service as a non-employee director. He also exercised stock options for 1,030 shares at $44.18 per share and sold 1,030 common shares in an open-market transaction at an average price of $81.8409 per share. After these transactions, he directly owned 10,047 common shares.